This content is machine translated EHA in Stockholm CAR-T cells – New therapeutic approach for multiple myeloma There are new therapeutic approaches in multiple myeloma. For example, the efficacy and safety of CAR-T cells are being studied. In particular, they could be applicable in the refractory and…
View Post 5 min This content is machine translated Multiple Myeloma “Myeloma therapy has made great strides in recent years” In an interview with InFo ONCOLOGY & HEMATOLOGY, Prof. Christoph Renner, MD, Onkozentrum Hirslanden, Zurich, discusses the latest therapeutic advances in multiple myeloma. In doing so, he answers questions such…
View Post 4 min This content is machine translated Multiple Myeloma Active ingredients at a glance At the EHA Congress in Milan, multiple myeloma was the focus of several events. What are the current results of proteasome inhibitors and immunomodulatory drugs and what is their promise…
View Post 3 min This content is machine translated Non-Hodgkin's Lymphoma Pomalidomide in high-risk patients. Because data on the efficacy of pomalidomide in high-risk relapsed/refractory multiple myeloma populations are sparse, a phase II study set out to evaluate the agent in patients with GEP70 or…
View Post 6 min This content is machine translated Non-Hodgkin's lymphoma and myelodysplastic syndrome What are the benefits of lenalidomide and pomalidomide? At the ASH Congress in New Orleans, the focus was on the efficacy and safety of lenalidomide plus low-dose dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.…
View Post 4 min This content is machine translated Multiple Myeloma and MDS Something has happened in therapy The diagnosis and treatment of multiple myeloma (MM) and myelodysplastic syndromes (MDS) have undergone great development in recent years. Modern diagnostic procedures became qualitatively better and more widely available, new…
